


Epredia to distribute Paige Digital Pathology Software globally

18 March 2021 | News

Epredia will have exclusive distribution rights in Japan along with the existing rights in the United States and major European countries



Epredia, a global leader in precision cancer diagnostics, and Paige, a global leader in AI-based diagnostic software in pathology, have announced today that they have entered into a commercial distribution agreement for Paige's comprehensive portfolio of diagnostic software solutions.

Under the terms of this agreement, Epredia has been appointed as a global distribution partner of the entire Paige portfolio of imaging diagnostic solutions. In addition, Epredia will have exclusive distribution rights in Japan. In the second quarter of 2021, Epredia will begin to commercialize the Paige solutions alongside existing Epredia products in the United States and major European Countries, further strengthening its comprehensive digital pathology portfolio that already includes the best-in-class CE-marked 3DHitech P1000 scanner*.

The Paige portfolio includes the Paige Platform, a comprehensive imaging solution comprised of a fast, zero-footprint viewer, storage capabilities and AI-based diagnostic software to help pathologists review cases and support their overall workflow.

The FDA-cleared and CE-marked Paige Platform features FullFocus™, an intuitive and responsive viewer for pathology scans that supports primary diagnosis and their Data Management solution for storage of pathology scans. The Paige Platform is designed to be compatible with existing pathology solutions, including most scanners, monitors, and laboratory information systems.

Paige's AI-based diagnostic software solutions are designed to increase the number of cases that can be reviewed and with greater confidence and accuracy. Currently Paige Prostate and Paige Breast are CE-marked and available for clinical use outside of the United States. Paige Prostate RUO and Paige Breast RUO are research-use only solutions that are available in the United States.

"We believe that digital pathology is a key part of cancer diagnostics of the future and are extremely excited to be entering into this partnership with Paige to commercialize their highly innovative portfolio of AI-based digital pathology solutions,"

explained John Marotta, President, EpreDia and Chief Executive Officer, PHC Holdings Corporation.

"This commercial partnership with EpreDia is an exciting step for Paige and we are thrilled to be working with one of the leading companies in anatomical pathology. EpreDia's extensive global commercial reach will support our efforts to expand our geographical footprint," said Leo Grady, Ph.D., Chief Executive Officer of Paige."